We are live on ! Find out more
ADAP

Adaptimmune Therapeutics
ADAP

Delisted

ADAP was delisted on the 27th of October, 2025.

Back to rankings

92 hedge funds and large institutions have $577M invested in Adaptimmune Therapeutics in 2021 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 30 increasing their positions, 23 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

157% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 7

30% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 23

27% more call options, than puts

Call options by funds: $2.49M | Put options by funds: $1.96M

21% more capital invested

Capital invested by funds: $476M → $577M (+$101M)

12% more funds holding

Funds holding: 82 → 92 (+10)

0.05% less ownership

Funds ownership: 11.97% → 11.92% (-0.05%)

Holders
92
Holders Change
+10
Holders Change %
+12.2%
% of All Funds
1.61%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
18
Increased
30
Reduced
23
Closed
7
Calls
$2.49M
Puts
$1.96M
Net Calls
+$531K
Net Calls Change
+$530K

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$11.4M
2
Marshall Wace
Marshall Wace
United Kingdom
+$6.97M
3
Baillie Gifford & Co
Baillie Gifford & Co
United Kingdom
+$5.06M
4
PHS
PFM Health Sciences
California
+$3.48M
5
Bank of America
Bank of America
North Carolina
+$3.23M

Top Sellers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$8.89M
2
Morgan Stanley
Morgan Stanley
New York
-$8.76M
3
ACA
Avoro Capital Advisors
New York
-$8.62M
4
Capital International Investors
Capital International Investors
California
-$5.63M
5
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
-$4.34M
Name Holding Trade Value Shares
Change 		Change in
Stake
AA
26
ALPS Advisors
Colorado
$985K -$63.8K -14,225 -7%
Man Group
27
Man Group
United Kingdom
$767K +$204K +45,437 +44%
WM
28
WS Management
Florida
$598K – – –
Vontobel Holding
29
Vontobel Holding
Switzerland
$533K +$13.5K +3,000 +3%
VWM
30
Vigilare Wealth Management
Arizona
$517K +$205K +45,700 +84%
EAM
31
Erste Asset Management
Austria
$468K +$404K +90,000 New
ACM
32
ACT Capital Management
Pennsylvania
$465K +$404K +90,000 New
ECM
33
ExodusPoint Capital Management
New York
$446K +$387K +86,202 New
SG Americas Securities
34
SG Americas Securities
New York
$440K -$675K -150,551 -64%
Point72 Asset Management
35
Point72 Asset Management
Connecticut
$394K -$8.89M -1,982,792 -96%
Geode Capital Management
36
Geode Capital Management
Massachusetts
$376K – – –
AA
37
AlphaCentric Advisors
Puerto Rico
$354K -$231K -51,500 -43%
Mitsubishi UFJ Asset Management
38
Mitsubishi UFJ Asset Management
Japan
$315K – – –
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
39
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
$312K -$4.34M -966,700 -94%
MWNA
40
Marshall Wace North America
New York
$304K +$264K +58,847 New
CSS
41
Cubist Systematic Strategies
Connecticut
$300K +$216K +48,054 +485%
VF
42
Virtu Financial
New York
$246K +$213K +47,542 New
VEA
43
Virtus ETF Advisers
New York
$245K -$11.1K -2,469 -5%
KBC Group
44
KBC Group
Belgium
$237K -$26.5K -5,900 -11%
Stifel Financial
45
Stifel Financial
Missouri
$229K +$3.8K +848 +2%
SFI
46
Susquehanna Fundamental Investments
Pennsylvania
$227K -$340K -75,790 -63%
HJIM
47
Henry James International Management
New York
$223K – – –
Citigroup
48
Citigroup
New York
$217K -$35.6K -7,932 -16%
Jane Street
49
Jane Street
New York
$216K +$50.4K +11,234 +37%
DekaBank Deutsche Girozentrale
50
DekaBank Deutsche Girozentrale
Germany
$215K – – –
1
2
3 4

ADAP Hedge Fund Activity: Q3 2021 in Review

92 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q3 2021, worth a combined $577M — up 21% from $476M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new ADAP positions and 7 closed out — a net gain of 11 holders — while 30 added to existing stakes and 23 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $11.4M. The largest seller was Point72 Asset Management, cutting an estimated $8.89M.

  • 92 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q3 2021, up from 82 in Q2 2021.
  • Funds reported $577M of Adaptimmune Therapeutics stock for Q3 2021, up 21% quarter-over-quarter.
  • 18 funds opened new Adaptimmune Therapeutics positions in Q3 2021 and 7 closed out, a net change of +11 holders.
  • The largest Adaptimmune Therapeutics buyer in Q3 2021 was Citadel Advisors, an estimated $11.4M added.
  • The largest Adaptimmune Therapeutics seller in Q3 2021 was Point72 Asset Management, an estimated $8.89M sold.

Based on aggregated 13F filings for Q3 2021.